Physician profile
Erin E Bales
NPI 1437714508
$3,004.77
in general payments reported to CMS, 2019-2025
50 companies · $1,170 in 2025
The $1,170 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $180 · 2022: $148 · 2023: $440 · 2024: $1,068 · 2025: $1,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,618 · Education: $59.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,618.36 |
| Education | $59.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $420.72 | 2023-2025 | Enhertu, Vanflyta, Injectafer |
| Janssen Biotech, INC. | $266.21 | 2023-2025 | Darzalex, Carvykti, Rybrevant |
| Abbvie INC. | $195.54 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $133.15 | 2023-2025 | Enhertu |
| Medtronic, INC. | $123.84 | 2021 | |
| Pfizer INC. | $105.04 | 2023-2025 | |
| Taiho Oncology, INC. | $93.91 | 2023-2025 | |
| Seagen INC. | $86.96 | 2022-2023 | Tukysa |
| Genentech USA, INC. | $81.16 | 2024-2025 | Tecentriq, Polivy, Kadcyla |
| Merck Sharp & Dohme LLC | $79.92 | 2024-2025 | Keytruda, Welireg |
| Tersera Therapeutics LLC | $78.26 | 2023-2025 | Zoladex, Xermelo |
| Tempus Ai, INC | $77.10 | 2024-2025 | Xt Cdx |
| Incyte Corporation | $73.96 | 2024-2025 | Jakafi, Niktimvo |
| Takeda Pharmaceuticals U.S.A., INC. | $72.76 | 2024-2025 | Alunbrig, Fruzaqla |
| Novartis Pharmaceuticals Corporation | $69.95 | 2025 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $65.98 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmaessentia USA Corporation | $61.46 | 2023-2025 | Besremi |
| Eisai INC. | $61.17 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $57.06 | 2024-2025 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $53.16 | 2023-2024 | Libtayo |
| Jazz Pharmaceuticals INC. | $52.11 | 2023-2025 | |
| Puma Biotechnology, INC. | $51.75 | 2024-2025 | |
| Kyowa Kirin, INC. | $44.98 | 2024-2025 | Poteligeo |
| Astellas Pharma US INC | $42.81 | 2023 | Xospata, Padcev |
| Nevro Corp. | $42.67 | 2021 | |
| Sobi, INC | $41.69 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $33.70 | 2022-2024 | Onivyde, Somatuline Depot |
| Amgen INC. | $27.81 | 2022-2023 | Kyprolis |
| Octapharma USA, INC. | $26.13 | 2024 | Octagam Immune Globulin (Human) |
| Janssen Pharmaceuticals, INC | $25.27 | 2024 | Rybrevant, Xarelto |
| Blueprint Medicines Corporation | $22.22 | 2023 | Ayvakit |
| Azurity Pharmaceuticals, INC. | $22.02 | 2025 | Danziten |
| Mirati Therapeutics, INC. | $21.55 | 2023 | Krazati |
| Geron Corporation | $20.98 | 2025 | Rytelo |
| Karyopharm Therapeutics INC. | $20.47 | 2023 | Xpovio |
| Alexion Pharmaceuticals, INC. | $20.16 | 2025 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $19.82 | 2025 | Qinlock, Romvimza |
| Coherus Oncology, INC. | $19.71 | 2024 | |
| Beone Medicines USA, INC. | $19.49 | 2025 | Brukinsa |
| Genzyme Corporation | $17.56 | 2023 | |
| Caris Mpi, INC. | $16.65 | 2025 | Mi Cancer Seek |
| Rigel Pharmaceuticals, INC. | $16.64 | 2024 | Tavalisse, Rezlidhia |
| Aveo Pharmaceuticals, INC. | $16.52 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.03 | 2024 | Opdivo |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Recordati_rare_diseases_inc. | $15.98 | 2025 | Enjaymo |
| Stemline Therapeutics INC. | $15.37 | 2023 | Orserdu |
| Bayer Healthcare Pharmaceuticals INC. | $15.26 | 2025 | |
| Myriad Genetic Laboratories, INC. | $13.06 | 2022 | |
| Allergan, INC. | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Bales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.